TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Silexion Therapeutics ( (SLXN) ) has issued an announcement.
On November 25, 2025, Silexion Therapeutics announced the successful completion of toxicology studies for SIL204, a next-generation RNA silencing therapy targeting mutated KRAS oncogenes, ahead of its planned Phase 2/3 clinical trial in locally advanced pancreatic cancer. The studies confirmed no systemic organ toxicity, allowing the company to proceed with regulatory submissions in Israel and Germany and stay on track to initiate the trial in Q2 2026. This advancement strengthens Silexion’s position in the biotechnology industry, offering a promising treatment modality for aggressive cancers and potentially improving survival rates for patients with pancreatic cancer.
The most recent analyst rating on (SLXN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference therapies for KRAS-driven cancers. The company is dedicated to creating innovative treatments for solid tumor cancers with mutated KRAS oncogenes, which are common oncogenic drivers in human cancers.
Average Trading Volume: 477,613
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.97M
For an in-depth examination of SLXN stock, go to TipRanks’ Overview page.